Innovation ranks high on Dr Reddy’s Laboratories prescription – The Financial Express
0
The fortunes of Indian drug makers are largely dependent on the generic medicines they make for the US market. But with consolidation in the US pharmaceutical supply chain hurting the earnings of Indian drug makers, at least one of them is trying to break the mould and become an innovator.
Hyderabad-based Dr Reddy’s Laboratories (DRL) is looking to move up the value chain and is planning to file two NDAs (new drug applications) with the US Food and Drugs Administration (USFDA) by the end of 2015. The two products that the company is indigenously developing are for the treatment of dermatological and neurological ailments respectively.
Read more – The Financial Express